| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8778668 | European Urology | 2017 | 10 Pages |
Abstract
Patients confronted with rare kidney cancers are often treated the same way as clear-cell renal cell carcinoma patients, despite little evidence from randomized trials. Molecular characterization of tumors to stratify patients may improve outcomes. Availability of potential agents and trials remain a problem. Collaboration among medical centers is important to pool scarce data.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Rachel H. Giles, Toni K. Choueiri, Daniel Y. Heng, Laurence Albiges, James J. Hsieh, W. Marston Linehan, Sumanta Pal, Deborah Maskens, Bill Paseman, Eric Jonasch, Gabriel Malouf, Ana M. Molina, Lisa Pickering, Brian Shuch, Sandy Srinivas,